Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Governor of the Bank of Japan: US Tariff Policy Will Impact Japanese Economy

Governor of the Bank of Japan: US Tariff Policy Will Impact Japanese Economy

金色财经金色财经2025/04/17 19:11
Show original

Kazuo Ueda, Governor of the Bank of Japan, stated on the 17th that US tariff policy will impact the Japanese economy and may have negative effects on international financial markets. Ueda mentioned that, besides directly affecting trade activities, US tariff policy also increases uncertainty, impacting the confidence of businesses and households. He believes that the US tariff policy will exert downward pressure on the Japanese economy. He indicated that it is now necessary to assess the impact of tariffs on the economic and price outlook without any preconceptions and, on that basis, prudently decide on appropriate financial policies.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"Orders remain as expected, but confidence has been re-evaluated." Bank of America: ASML three giants’ cooperation strengthens the long-term High-NA roadmap.

On Tuesday, ASML (ASML.US) became the focus of the market as Bank of America praised the company's additional chip manufacturing equipment supply agreements with TSMC (TSM.US), Intel (INTC.US), and Samsung.

智通财经2026/09/09 08:11
"Orders remain as expected, but confidence has been re-evaluated." Bank of America: ASML three giants’ cooperation strengthens the long-term High-NA roadmap.

Novartis (NVS.US) cardiovascular therapy trial "misfire" drags down Amgen (AMGN.US): stock price plunges to a ten-year low, BMO swiftly downgrades rating

Amgen's stock posted its biggest single-day decline since 2016 on Tuesday, after Novartis announced that a heart disease therapy jointly developed with Ionis Pharmaceuticals suffered a setback in late-stage clinical trials. Meanwhile, BMO downgraded the pharmaceutical giant's rating from "Outperform" to "Market Perform," citing the failure of its candidate drug pelacarsen to meet expectations in its phase III clinical trial.

智通财经2026/09/09 08:11
Novartis (NVS.US) cardiovascular therapy trial "misfire" drags down Amgen (AMGN.US): stock price plunges to a ten-year low, BMO swiftly downgrades rating

NASA contractor Rothe Development rushes to Nasdaq, plans to raise $50 millions

Rothe Development, a contractor that provides engineering and mission operations services to NASA and other federal agencies, filed on Tuesday with the SEC to raise up to $50 million through an initial public offering (IPO).

智通财经2026/09/09 08:11
NASA contractor Rothe Development rushes to Nasdaq, plans to raise $50 millions